Agriculture Purchase Commitments Under the U.S.-China Trade Deal: The Case of Beef

Simon Lester andHuan ZhuYesterday, President Trump and Chinese Vice Premier Liu He signed a " phase one "U.S.-China trade deal. A " phase two " deal may be coming, although the timing is unclear, and many people (including us) are skeptical that it will happen any time soon. There are some technical and complicated parts of the phase one deal, and it will take some time to digest it all and come up with an overall evaluation. But it's worth exploring some specific aspects right away. One of the most talked about parts of the phase one deal is the commitments by China to purchase large amounts of U.S. products, including agricultural products. Article 6.2, paragraph 1 of the deal has broad details of these purchases:During the two-year period from January 1, 2020 through December 31, 2021, China shall ensure that purchases and imports into China from the United States of the manufactured goods, agricultural goods, energy products, and services identified in Annex 6.1 exceed the corresponding 2017 baseline amount by no less than $200 billion.Given that U.S. exports to China in 2017 were about $180 billion, an additional $200 billion over two years would be a massive increase. The deal further divides up these purchases into manufactured goods, agricultural goods, energy, and services, with specified amounts for each. It then provides sub-categories, but it does not publicly break down the purchase amounts by sub-category (apparently it does so in a confident...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs

Related Links:

Authors: Lisicki M, Schoenen J Abstract Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavourable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and much better tolerated, but they are expensive and may not influence brain dysfunctions upstream in the pathophysiological cascade of migraine, including premonitory and aura symptoms. Biochemical and clinical studies suggest that there may be another complimentary treatment strategy, the one that targets the undere...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Ankur Khajuria
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Hugues Chabriat, Claudio L Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M Hermann, Katharina ALTHAUS, Sergi AMARO, Hee-Joon BAE, Zbigniew BAK, Leonardo BARBARINI, Pietro BASSI, Rodrigo BAZAN, Daniel BERECZKI, Tomasz BERKOWICZ, Joerg BERROUSCHOT, Dylan BLACQUIERE, Waldemar BROLASummaryBackgroundS44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical exc...
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s):
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s):
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Matthew J Rowland, Tonny Veenith, Peter J Hutchinson, Gavin D Perkins, SOS Trial Investigators
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Joanna Laurson-Doube, Nick Rijke, Kathleen Costello, Jennifer McDonell, Gavin Giovannoni, Brenda Banwell, Peer Baneke
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Peter J Goadsby, Ali R Rezai, David W Dodick
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Arne May
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Steven C Cramer
Source: The Lancet Neurology - Category: Neurology Source Type: research
More News: American Health | Argentina Health | Australia Health | Brazil Health | China Health | Government | Hong Kong Health | Hormones | Meat | Men | New Zealand Health | Trump | Uruguay Health | USA Health